Charles James Ryan, MD
We post reviews for MSK healthcare providers who have at least 30 patient experience surveys completed. If you do not see reviews for a provider, it may be because they do not yet have enough survey responses, or the provider may not be part of the group of healthcare providers included in the survey.
Only outpatient providers are included in the survey. Healthcare providers who only work in the hospital or in urgent care are not included in the survey. Pathologists or researchers who do not provide direct care to patients do not have reviews.
Areas of Expertise
Conditions I Treat
- Prostate cancer and conditions
- Testicular cancer
Get to Know Me
I am a genitourinary medical oncologist who specializes in treating prostate cancer, especially prostate cancer at an advanced stage that has spread, or metastasized, to other parts of the body. I see patients at the Sidney Kimmel Center for Prostate and Urologic Cancers in New York City and at Memorial Sloan Kettering Monmouth in New Jersey.
I take pride in getting to know my patients and their families and educating them about their diagnosis. I also take the time to explain the various treatment options available for prostate cancer, including hormonal therapies, chemotherapy, targeted therapy, and radiogland therapy – a type of treatment that delivers radiation directly to targeted cancer cells. As a lifelong clinician, I look forward to establishing long-term relationships with my patients.
I also engage in research and have led many clinical trials and research teams that focus on the biology, treatment, and supportive care for prostate cancer. In the past, I have received research funding from the National Institutes of Health, the Department of Defense Prostate Cancer Research Program, and the Prostate Cancer Foundation.
I have published more than 200 articles and chapters in the world’s leading medical journals. I am the author of the book, The Virility Paradox: The Vast Influence of Testosterone on Our Bodies, Minds, and the World We Live In. In the past, I have served as Chair of the National Cancer Institute’s GU Steering Committee’s Prostate Cancer Task Force and as Chief Executive Officer of the Prostate Cancer Foundation. I serve as Medical Director of the Prostate Cancer Clinical Trials Consortium, and I am a member of the Advanced Prostate Cancer Consensus Conference.
I'm a genitourinary (GU) medical oncologist, which is a cancer doctor who specializes in genitourinary (jeh-nih-toh-YOOR-ih-nayr-ee) cancers. This includes bladder, kidney, penis, prostate, and testicular cancers.
- Attending Physician
Conditions I Treat
- Prostate cancer and conditions
- Testicular cancer
Education
- BA, Marquette University
- MD, University of Wisconsin
Residencies
- University of Wisconsin Hospitals and Clinics
Fellowships
- Medical Oncology, Memorial Sloan Kettering Cancer Center
Board Certifications
- Medical Oncology
Awards and Honors
- Fellowship Research Mentor Award, University of Minnesota (2021)
- Director's Service Award, National Cancer Institute (2018)
- Marc A Shuman Mentoring Award, University of California (2017)
- Fellowship Program Mentor Award, University of California (2011)
- Commitment to Patient Care Award, University of California (2008)
Insurance Information
Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.
In Network Coverage Type
HMO, EPO PPO, POS, Transplant
In Network Coverage Type
PPO
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
PPO, HMO
In Network Coverage Type
HMO, PPO
In Network Coverage Type
HMO
In Network Coverage Type
HMO, PPO
In Network Coverage Type
HMO, EPO PPO, POS
In Network Coverage Type
Supplemental
In Network Coverage Type
PPO, POS, HMO
In Network Coverage Type
POS, EPO, HMO
In Network Coverage Type
State Government
In Network Coverage Type
State Government
In Network Coverage Type
PPO, POS, EPO, HMO
Offers a qualified health plan from the Health Insurance Marketplace. Call Emblem to learn more.
In Network Coverage Type
HMO
In Network Coverage Type
PPO, HMO
In Network Coverage Type
HMO
In Network Coverage Type
PPO
In Network Coverage Type
HMO, EPO
Offers a qualified health plan from the Health Insurance Marketplace. Call Fidelis to learn more.
In Network Coverage Type
HMO
In Network Coverage Type
PPO
In Network Coverage Type
State Government
In Network Coverage Type
EPO, HMO, PPO, POS
Offers a qualified health plan from the Health Insurance Marketplace. Call Healthfirst to learn more.
In Network Coverage Type
HMO
In Network Coverage Type
PPO EPO
In Network Coverage Type
HMO
In Network Coverage Type
PPO
In Network Coverage Type
EPO
In Network Coverage Type
EPO
In Network Coverage Type
TBD
In Network Coverage Type
PPO, POS, EPO
In Network Coverage Type
Federal Government
In Network Coverage Type
HMO
City Employee Health Plans (Gold and Gold Care)
In Network Coverage Type
Supplemental
In Network Coverage Type
PPO/OAP
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
HMO/EPO
In Network Coverage Type
PPO, EPO
In Network Coverage Type
State Government
In Network Coverage Type
PPO, POS, HMO
In Network Coverage Type
PPO, HMO
In Network Coverage Type
PPO, POS
In Network Coverage Type
PPO, POS, HMO
Don't see your carrier or plan? We can help you understand your coverage.
If you don't have health insurance or are worried that your care may not be fully covered, our financial assistance programs may be able to help.
If you have questions about insurance, call us at 646-497-9176.
Make an Appointment
Contact and Location
Dr. Ryan sees patients at two locations.
Looking to see a doctor at a different location? See all MSK locations.
Colleagues
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
Clinical Trials
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Search clinical trialsResearch and Publications
Bergom HE, Boytim E, McSweeney S, Sadeghipour N, Elliott A, Passow R, Toye E, Li X, Likasitwatanakul P, Geynisman DM, Dehm SM, Halabi S, Sharifi N, Antonarakis ES, Ryan CJ, Hwang J. Androgen production, uptake, and conversion (APUC) genes define prostate cancer patients with distinct clinical outcomes. JCI Insight. 2024 Aug 29:e183158. doi: 10.1172/jci.insight.183158. Epub ahead of print. PMID: 39207857.
Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PF, Basch E, Small EJ, Saad F, Schrijvers D, Van Poppel H, Mukherjee SD, Suttmann H, Gerritsen WR, Flaig TW, George DJ, Yu EY, Efstathiou E, Pantuck A, Winquist E, Higano CS, Taplin ME, Park Y, Kheoh T, Griffin T, Scher HI, Rathkopf DE; COU-AA-302 Investigators. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013 Jan 10;368(2):138-48. doi: 10.1056/NEJMoa1209096. Epub 2012 Dec 10. Erratum in: N Engl J Med. 2013 Feb 7;368(6):584. PMID: 23228172; PMCID: PMC3683570.
Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN, Miller K, Logothetis CJ, Shore ND, Small EJ, Carles J, Flaig TW, Taplin ME, Higano CS, de Souza P, de Bono JS, Griffin TW, De Porre P, Yu MK, Park YC, Li J, Kheoh T, Naini V, Molina A, Rathkopf DE; COU-AA-302 Investigators. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015 Feb;16(2):152-60. doi: 10.1016/S1470-2045(14)71205-7. Epub 2015 Jan 16. PMID: 25601341.
Morris MJ, Molina A, Small EJ, de Bono JS, Logothetis CJ, Fizazi K, de Souza P, Kantoff PW, Higano CS, Li J, Kheoh T, Larson SM, Matheny SL, Naini V, Burzykowski T, Griffin TW, Scher HI, Ryan CJ. Radiographic progression-free survival as a response biomarker in metastatic castration-resistant prostate cancer: COU-AA-302 results. J Clin Oncol. 2015 Apr 20;33(12):1356-63. doi: 10.1200/JCO.2014.55.3875. Epub 2015 Jan 26. PMID: 25624432; PMCID: PMC4881370.
Ryan CJ, Molina A, Li J, Kheoh T, Small EJ, Haqq CM, Grant RP, de Bono JS, Scher HI. Serum androgens as prognostic biomarkers in castration-resistant prostate cancer: results from an analysis of a randomized phase III trial. J Clin Oncol. 2013 Aug 1;31(22):2791-8. doi: 10.1200/JCO.2012.45.4595. Epub 2013 Jul 1. PMID: 23816964; PMCID: PMC5569674.
Visit PubMed for a full listing of Dr. Ryan’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
See all on PubMedPatient Reviews
Your trust is our main concern
We strive to keep reviews trustworthy, honest and fair. Learn more about our patient experience reviews.